AR036337A1 - Composicion farmaceutica inyectable que comprende un peptido antagonista de gnrh, un conjunto farmaceutico, metodo de tratamiento y uso de un peptido antagonista de gnrh. - Google Patents
Composicion farmaceutica inyectable que comprende un peptido antagonista de gnrh, un conjunto farmaceutico, metodo de tratamiento y uso de un peptido antagonista de gnrh.Info
- Publication number
- AR036337A1 AR036337A1 ARP020102599A ARP020102599A AR036337A1 AR 036337 A1 AR036337 A1 AR 036337A1 AR P020102599 A ARP020102599 A AR P020102599A AR P020102599 A ARP020102599 A AR P020102599A AR 036337 A1 AR036337 A1 AR 036337A1
- Authority
- AR
- Argentina
- Prior art keywords
- gnrh antagonist
- peptide
- antagonist peptide
- gel
- treatment
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 239000002474 gonadorelin antagonist Substances 0.000 title abstract 4
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 238000010254 subcutaneous injection Methods 0.000 abstract 2
- 239000007929 subcutaneous injection Substances 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 230000004720 fertilization Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000010255 intramuscular injection Methods 0.000 abstract 1
- 239000007927 intramuscular injection Substances 0.000 abstract 1
- 108010034529 leucyl-lysine Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000005426 pharmaceutical component Substances 0.000 abstract 1
- 208000006155 precocious puberty Diseases 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0117057.0A GB0117057D0 (en) | 2001-07-12 | 2001-07-12 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036337A1 true AR036337A1 (es) | 2004-09-01 |
Family
ID=9918396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102599A AR036337A1 (es) | 2001-07-12 | 2002-07-11 | Composicion farmaceutica inyectable que comprende un peptido antagonista de gnrh, un conjunto farmaceutico, metodo de tratamiento y uso de un peptido antagonista de gnrh. |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20040038903A1 (https=) |
| EP (1) | EP1404357B1 (https=) |
| JP (1) | JP4845166B2 (https=) |
| AR (1) | AR036337A1 (https=) |
| AT (1) | ATE452648T1 (https=) |
| DE (1) | DE60234831D1 (https=) |
| DK (1) | DK1404357T3 (https=) |
| ES (1) | ES2338217T3 (https=) |
| GB (1) | GB0117057D0 (https=) |
| MY (1) | MY139203A (https=) |
| PT (1) | PT1404357E (https=) |
| UY (1) | UY27378A1 (https=) |
| WO (1) | WO2003006049A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| BRPI0314546B8 (pt) | 2002-09-27 | 2021-05-25 | Zentaris Gmbh | composição de gel farmacêutico compreendendo peptídeos farmaceuticamente atvos com liberação sustentada, método para a produção dos mesmos kit. |
| WO2005035717A2 (en) | 2003-10-03 | 2005-04-21 | Thorn Bioscience, Llc | Process for the synchronization of ovulation for timed breeding without heat detection |
| GB0511269D0 (en) | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
| AU2007339280B2 (en) * | 2006-12-21 | 2013-12-05 | Stryker Corporation | Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents |
| TWI539959B (zh) | 2008-02-11 | 2016-07-01 | 菲瑞茵國際中心股份有限公司 | 治療轉移階段攝護腺癌的方法 |
| RU2568839C2 (ru) | 2009-04-23 | 2015-11-20 | ДжейБиЭс Юнайтид Энимал Хэлс II ЛЛК | Способ и композиция для синхронизации времени осеменения |
| MX2011011431A (es) * | 2009-05-01 | 2012-02-23 | Ferring Bv | Composicion para el tratamiento de cancer de prostata. |
| JO3550B1 (ar) * | 2009-05-01 | 2020-07-05 | Ferring Int Center Sa | مركب لمعالجة سرطان البروستاتا |
| TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| LT2632934T (lt) | 2010-10-27 | 2017-01-10 | Ferring B.V. | Degarelikso ir jo tarpinių darinių gamybos būdas |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| WO2013104745A1 (en) * | 2012-01-13 | 2013-07-18 | Ferring Bv | Pharmaceutical composition |
| PL4512390T1 (pl) | 2012-06-01 | 2025-09-01 | Ferring B.V. | Wytwarzanie degareliksu |
| ITMI20121638A1 (it) | 2012-10-02 | 2014-04-03 | Marco Sbracia | Utilizzo di degarelix nel trattamento dell'endometriosi e di patologie ad essa correlate |
| EP2925339B1 (en) | 2012-11-28 | 2020-04-29 | United-AH II, LLC | Method for synchronizing time of insemination in gilts |
| US10681261B2 (en) * | 2012-11-30 | 2020-06-09 | 3I Avi, Llc | Inspection system |
| TW201625218A (zh) * | 2014-04-18 | 2016-07-16 | Ｊｂｓ聯合動物保健有限責任公司 | 製造含ｇｎｒｈ凝膠之方法 |
| BR112019014192A2 (pt) * | 2017-01-30 | 2020-02-11 | Antev Limited | Composição compreendendo pelo menos um antagonista de gnrh |
| WO2019110688A1 (en) | 2017-12-05 | 2019-06-13 | Ferring B.V. | A composition comprising degarelix for use in the treatment of breast cancer |
| EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US200486A (en) * | 1878-02-19 | Improvement in apparatus for attaching harness to the shafts | ||
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| DE69214818T2 (de) * | 1991-04-25 | 1997-02-27 | Romano S.-Cergue Deghenghi | LHRH-Antagonisten |
| SI9300468A (en) * | 1992-10-14 | 1994-06-30 | Hoffmann La Roche | Injectable composition for the sustained release of biologically active compounds |
| US5506207A (en) * | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
| US5595760A (en) * | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5860957A (en) * | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| US5821230A (en) * | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| US5925730A (en) * | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
| FR2776520B1 (fr) * | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
| US20020103131A1 (en) * | 2001-01-26 | 2002-08-01 | Jacobson Jill D. | Prevention of diabetes by administration of GnRH antagonists |
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| AR042815A1 (es) * | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| EP1891964A1 (en) * | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
| TWI539959B (zh) * | 2008-02-11 | 2016-07-01 | 菲瑞茵國際中心股份有限公司 | 治療轉移階段攝護腺癌的方法 |
| ES2589322T3 (es) * | 2008-02-11 | 2016-11-11 | Safety Syringes, Inc. | Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución |
| MX2011011431A (es) * | 2009-05-01 | 2012-02-23 | Ferring Bv | Composicion para el tratamiento de cancer de prostata. |
| TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| EP2447276A1 (en) * | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| LT2632934T (lt) * | 2010-10-27 | 2017-01-10 | Ferring B.V. | Degarelikso ir jo tarpinių darinių gamybos būdas |
| JO3755B1 (ar) * | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| KR20140063602A (ko) * | 2011-07-15 | 2014-05-27 | 훼링 비.브이. | 피코설페이트 조성물을 투여하여 대장내시경의 시술 시기를 조절하는 방법 |
-
2001
- 2001-07-12 GB GBGB0117057.0A patent/GB0117057D0/en not_active Ceased
-
2002
- 2002-07-03 MY MYPI20022511A patent/MY139203A/en unknown
- 2002-07-08 EP EP02749000A patent/EP1404357B1/en not_active Expired - Lifetime
- 2002-07-08 DK DK02749000.2T patent/DK1404357T3/da active
- 2002-07-08 JP JP2003511855A patent/JP4845166B2/ja not_active Expired - Lifetime
- 2002-07-08 US US10/380,623 patent/US20040038903A1/en not_active Abandoned
- 2002-07-08 AT AT02749000T patent/ATE452648T1/de active
- 2002-07-08 PT PT02749000T patent/PT1404357E/pt unknown
- 2002-07-08 WO PCT/GB2002/003116 patent/WO2003006049A1/en not_active Ceased
- 2002-07-08 ES ES02749000T patent/ES2338217T3/es not_active Expired - Lifetime
- 2002-07-08 US US10/483,325 patent/US20050245455A1/en not_active Abandoned
- 2002-07-08 DE DE60234831T patent/DE60234831D1/de not_active Expired - Lifetime
- 2002-07-11 UY UY27378A patent/UY27378A1/es not_active Application Discontinuation
- 2002-07-11 AR ARP020102599A patent/AR036337A1/es not_active Application Discontinuation
-
2008
- 2008-06-11 US US12/155,897 patent/US20090018085A1/en not_active Abandoned
-
2010
- 2010-10-08 US US12/901,270 patent/US20110053846A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT1404357E (pt) | 2010-03-16 |
| MY139203A (en) | 2009-08-28 |
| EP1404357B1 (en) | 2009-12-23 |
| DK1404357T3 (da) | 2010-05-03 |
| ATE452648T1 (de) | 2010-01-15 |
| ES2338217T3 (es) | 2010-05-05 |
| JP2005511491A (ja) | 2005-04-28 |
| US20040038903A1 (en) | 2004-02-26 |
| DE60234831D1 (de) | 2010-02-04 |
| EP1404357A1 (en) | 2004-04-07 |
| US20050245455A1 (en) | 2005-11-03 |
| US20090018085A1 (en) | 2009-01-15 |
| UY27378A1 (es) | 2003-02-28 |
| GB0117057D0 (en) | 2001-09-05 |
| JP4845166B2 (ja) | 2011-12-28 |
| WO2003006049A1 (en) | 2003-01-23 |
| US20110053846A1 (en) | 2011-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036337A1 (es) | Composicion farmaceutica inyectable que comprende un peptido antagonista de gnrh, un conjunto farmaceutico, metodo de tratamiento y uso de un peptido antagonista de gnrh. | |
| EA200600190A1 (ru) | Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона | |
| BRPI0809931B8 (pt) | antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo | |
| CO5271697A1 (es) | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona | |
| DK0462189T3 (da) | Kombinationsterapi til behandling af østrogenfølsomme sygdomme | |
| HN2003000100A (es) | Compuestos utiles en terapia | |
| SE0100567D0 (sv) | Compounds | |
| ATE391708T1 (de) | Verbindungen und gemische zur verabreichung eines aktiven agens | |
| PE20060879A1 (es) | Formulacion anticuerpo anti a beta | |
| JP2005511491A5 (https=) | ||
| BRPI0412327A (pt) | derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina | |
| ES2206622T3 (es) | Uso de un analogo de hormona liberadora de gonadotropina. | |
| HN2001000225A (es) | Composicion blanqueante dental y procedimiento que emplea un agente blanqueante acido dicarboxilico | |
| PE20070437A1 (es) | FORMULACION ACUOSA hFSH | |
| DK0973801T3 (da) | GnRH-antagonister | |
| UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
| DE60033649D1 (de) | Verbindungen und therapeutische methoden | |
| PE20051054A1 (es) | Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento | |
| AR049262A1 (es) | Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias | |
| ATE412412T1 (de) | Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1 -pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata-oder gebahrmutterkrebs | |
| MX2022003100A (es) | Un inmunoterapeutico para el tratamiento del cancer de prostata. | |
| GT200100251A (es) | Procedimiento para la preparacion de imidazotriazinonas substituidas con sulfonamida | |
| ATE557007T1 (de) | Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen | |
| PE20000176A1 (es) | Compuestos inhibidores de metaloproteasas de matriz | |
| MX2022011527A (es) | Formulaciones de oligosacaridos de agonistas del receptor opioide kappa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |